[go: up one dir, main page]

AU2003263717A1 - A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES - Google Patents

A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES

Info

Publication number
AU2003263717A1
AU2003263717A1 AU2003263717A AU2003263717A AU2003263717A1 AU 2003263717 A1 AU2003263717 A1 AU 2003263717A1 AU 2003263717 A AU2003263717 A AU 2003263717A AU 2003263717 A AU2003263717 A AU 2003263717A AU 2003263717 A1 AU2003263717 A1 AU 2003263717A1
Authority
AU
Australia
Prior art keywords
glucocorticosteroid
agonist
treatment
combination
long
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003263717A
Inventor
Jan Trofast
Gunilla Westergren-Thorsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0202837A external-priority patent/SE0202837D0/en
Priority claimed from SE0300106A external-priority patent/SE0300106D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2003263717A1 publication Critical patent/AU2003263717A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003263717A 2002-09-25 2003-09-24 A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES Abandoned AU2003263717A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0202837A SE0202837D0 (en) 2002-09-25 2002-09-25 New use
SE0202837-1 2002-09-25
SE0300106A SE0300106D0 (en) 2003-01-16 2003-01-16 New use
SE0300106-2 2003-01-16
PCT/SE2003/001486 WO2004028545A1 (en) 2002-09-25 2003-09-24 A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES

Publications (1)

Publication Number Publication Date
AU2003263717A1 true AU2003263717A1 (en) 2004-04-19

Family

ID=32044762

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003263717A Abandoned AU2003263717A1 (en) 2002-09-25 2003-09-24 A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES

Country Status (2)

Country Link
AU (1) AU2003263717A1 (en)
WO (1) WO2004028545A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2534693A1 (en) * 2003-08-05 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising steroids and a betamimetic
BRPI0613034A8 (en) * 2005-07-14 2018-01-02 Lipothera Inc injectable formulation for fat tissue accumulation, injectable formulation and method for treating fat accumulation, and method for reducing fat tissue.
MX2009004198A (en) 2006-10-17 2009-10-19 Lithera Inc Methods, compositions, and formulations for the treatment of thyroid eye disease.
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
CN105412122A (en) 2010-07-16 2016-03-23 希普拉有限公司 Pharmaceutical composition comprising R(+) budesonide and one or more bronchodilators
US10179139B2 (en) 2010-10-12 2019-01-15 Cipla Limited Pharmaceutical composition
GEP201606551B (en) 2010-11-24 2016-10-10 Novamedica Llc Selective, lipophilic, and long-acting beta agonists monotherapeutic formulations tions and methods for cosmetic treatment of adiposity and contour bulging
CN102247380A (en) * 2011-08-19 2011-11-23 北京阜康仁生物制药科技有限公司 Compound preparation with budesonide and indacaterol as the active components
MX2014011576A (en) 2012-04-11 2014-11-21 Cipla Ltd Pharmaceutical composition comprising arformoterol and fluticasone furoate.
EP4591936A3 (en) 2015-03-23 2025-10-15 Tianli Biotech Pty Ltd Treatment of respiratory diseases
WO2020093098A1 (en) 2018-11-07 2020-05-14 The University Of Melbourne Novel compounds for the treatment of respiratory diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006775A1 (en) * 1988-12-14 1990-06-28 Liposome Technology, Inc. A novel nonphospholipid liposome composition for sustained release of drugs
US5043165A (en) * 1988-12-14 1991-08-27 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs
WO1993011773A1 (en) * 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
US5376359A (en) * 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
JP2947945B2 (en) * 1995-12-29 1999-09-13 グラクソ、グループ、リミテッド 21- (2-Oxotetrahydrofuran) thiopregnane Derivatives, Methods for Producing Them, and Pharmaceutical Compositions Containing Them
SK122199A3 (en) * 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
EP1009408A1 (en) * 1997-06-27 2000-06-21 Astra Aktiebolag New combination of antiasthma medicaments
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US20030026766A1 (en) * 2000-04-13 2003-02-06 Mark Sanders Medicaments for treating respiratory disorders comprising formoterol and fluticasone
PE20011227A1 (en) * 2000-04-17 2002-01-07 Chiesi Farma Spa PHARMACEUTICAL FORMULATIONS FOR DRY POWDER INHALERS IN THE FORM OF HARD AGGLOMERATES
GB0009617D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
KR100787073B1 (en) * 2000-06-28 2007-12-21 글리코파이, 인크. Method for preparing modified glycoprotein
AR030516A1 (en) * 2000-08-31 2003-08-20 Glaxo Group Ltd USE OF A COMBINATION OF SALMETEROL AND FLUTICASONA

Also Published As

Publication number Publication date
WO2004028545A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
AU2003214945A1 (en) Multi-function catheter and use thereof
AU2003224638A1 (en) PDPK1s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2003243388A1 (en) Oral irrigation and/or brushing devices and/or methods
AU2003288050A1 (en) Selective stimulation with selective water reduction
AU2003300021A1 (en) Thiosemicarbazones as anti-virals and immunopotentiators
AU2003279819A8 (en) Shrimp and the production thereof
AU2003297037A1 (en) Illuminant and method
AU2003250497A1 (en) Creating and conducting a reverse auction
AU2003295551A1 (en) Wiping articles and their use
AU2003251965A1 (en) Post-defribillation pacing methods and devices
AU2003246083A1 (en) Ferrocene compound and use thereof
AU2003263717A1 (en) A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
AU2003239610A1 (en) Tiled biochips and the methods of making the same
AU2003215257A1 (en) Modified defensins and their use
AU2003224956A1 (en) Reference structures and reference structure enhanced tomography
AU2003206945A1 (en) Use of proteinase inhibitors in the treatment of autoimmune diseases
AU2003281691A1 (en) Furoisoquinoline derivative and use thereof
AU2003293939A1 (en) Polymer-containing pyrrolidone-4-carboxylic acid groups and the use thereof
AU2003232785A1 (en) Novel anthracene derivatives and the use thereof as a medicament
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
AU2003302173A1 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
AU2003286392A1 (en) 1microarrays and production thereof
AU2003220265A1 (en) Tamperproof and counterfeit-resistant structure
AU2002953589A0 (en) S wand
AU2003294687A1 (en) Stethoscope with timer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase